Supernus Pharmaceuticals, Inc.

SUPN

US8684591089

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-09-18 EDT			5-day change	1st Jan Change
31.84 ^USD	+0.38%		+2.45%	+10.02%

09-04	Transcript : Supernus Pharmaceuticals, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-04-2024 04:30 PM
08-19	Sector Update: Health Care Stocks Edge Higher Premarket Monday	MT

Supernus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 08, 2024 at 04:05 pm

Supernus Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 143.64 million compared to USD 153.76 million a year ago. Net income was USD 0.124 million compared to USD 16.95 million a year ago.

Latest news about Supernus Pharmaceuticals, Inc.

Transcript : Supernus Pharmaceuticals, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-04-2024 04:30 PM	09-04
Sector Update: Health Care Stocks Edge Higher Premarket Monday	08-19	MT
Supernus Pharmaceuticals Says US FDA Accepts NDA Resubmission for Potential Parkinson's Related Treatment Device	08-19	MT
Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA	08-19	CI
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q2 Revenue $168.3M, vs. Street Est of $148.9M	08-06	MT
Transcript : Supernus Pharmaceuticals, Inc., Q2 2024 Earnings Call, Aug 06, 2024	08-06
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-06	CI
Supernus Pharmaceuticals, Inc. Raises Financial Guidance for the Full Year 2024	08-06	CI
Supernus Pharmaceuticals Resubmits Marketing Application for Parkinson's Treatment Device	08-02	MT
Supernus Resubmits New Drug Application for Parkinson's Treatment Device	08-01	DJ
Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to Russell Small Cap Comp Value Index	06-30	CI
Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to Russell 2500 Value Index	06-30	CI
Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to Russell 3000 Value Index	06-30	CI
Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to Russell 2000 Value Index	06-30	CI
Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to Russell 2000 Value-Defensive Index	06-30	CI
Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) added to Russell 3000E Value Index	06-30	CI
Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study	05-23	MT
Transcript : Supernus Pharmaceuticals, Inc. - Special Call	05-23
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M	05-08	MT
Supernus Pharmaceuticals, Inc. Seeks M&A	05-08	CI
Transcript : Supernus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024	05-08	CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America	05-07	MT
M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Licensing Agreement with Supernus for Qelbree® (Viloxazine Xr) in Latin America	05-07	CI

Chart Supernus Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâs Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Employees

652

Sector

Pharmaceuticals

Calendar

2024-11-04 - Q3 2024 Earnings Release (Projected)

More about the company